BFM
CYTK icon

Boothbay Fund Management’s Cytokinetics CYTK Stock Holding History

Boothbay Fund Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.8M Sell
68,092
-36,353
-35% -$2.61M 0.08% 305
2026
Q1 		$6.88M Buy
104,445
+47,992
+85% +$3.05M 0.09% 227
2025
Q4 		$3.59M Sell
56,453
-35,363
-39% -$2.2M 0.05% 400
2025
Q3 		$5.05M Buy
91,816
+10,020
+12% +$413K 0.07% 315
2025
Q2 		$2.7M Sell
81,796
-404
-0.5% -$14.1K 0.05% 428
2025
Q1 		$3.3M Sell
82,200
-1,170
-1% -$53.8K 0.09% 311
2024
Q4 		$3.92M Sell
83,370
-7,347
-8% -$382K 0.1% 289
2024
Q3 		$4.79M Sell
90,717
-2,183
-2% -$122K 0.11% 264
2024
Q2 		$5.03M Sell
92,900
-2,979
-3% -$180K 0.12% 224
2024
Q1 		$6.72M Buy
95,879
+53,147
+124% +$4.11M 0.13% 152
2023
Q4 		$3.57M Buy
+42,732
New +$1.55M 0.09% 306
2023
Q2 		– Sell
-11,862
Closed -$417K – 1911
2023
Q1 		$417K Buy
+11,862
New +$484K 0.01% 1331
2022
Q3 		– Sell
-8,762
Closed -$422K – 2308
2022
Q2 		$344K Buy
+8,762
New +$353K 0.01% 1375
2021
Q3 		– Sell
-12,217
Closed -$242K – 1951
2021
Q2 		$242K Sell
12,217
-616
-5% -$14.5K 0.01% 1407
2021
Q1 		$298K Sell
12,833
-10,103
-44% -$216K 0.01% 1193
2020
Q4 		$477K Buy
+22,936
New +$419K 0.02% 767
2019
Q4 		– Sell
-11,411
Closed -$130K – 866
2019
Q3 		$130K Buy
+11,411
New +$143K 0.01% 686
2018
Q3 		– Sell
-18,928
Closed -$157K – 814
2018
Q2 		$157K Buy
+18,928
New +$158K 0.01% 652

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boothbay Fund Management's CYTK Position: Q2 2026 in Review

Boothbay Fund Management reduced its Cytokinetics (CYTK) stake by 35% in Q2 2026, selling an estimated $2.61M and leaving 68,092 shares worth $5.8M. The position accounts for 0.08% of the portfolio, ranked #305.

Boothbay Fund Management first reported a position in CYTK in Q2 2018 and has held it in 18 quarters since. The position peaked at $6.88M in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Boothbay Fund Management held 68,092 shares of Cytokinetics worth $5.8M as of Q2 2026.
  • Boothbay Fund Management sold 36,353 Cytokinetics shares in Q2 2026, an estimated $2.61M.
  • Cytokinetics made up 0.08% of Boothbay Fund Management's portfolio in Q2 2026, its #305 holding.
  • Boothbay Fund Management first reported a position in Cytokinetics in Q2 2018 and has held it in 18 quarters since.
  • Boothbay Fund Management's Cytokinetics position peaked at $6.88M in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.